Recombinetics (RCI) aims at providing gene-editing solutions for some of the world’s most intractable challenges, from improving human health to sustainably feeding an ever-growing population. Founded in 2008, RCI is widely recognized as the global thought leader in livestock gene editing and applied technology. RCI has developed a proprietary DNA toolkit for deployment in agriculture, regenerative medicine, and therapeutic development, commercialized through its subsidiaries Acceligen, Regenevida, and Surrogen.
Delivering viable products and generating revenues today, RCI is rapidly growing to broadly commercialize the sale and distribution of its gene-edited animals. RCI far outpaces its competitors in intellectual property with a global patent portfolio of 30 issued US patents, more than 200 additional applications filed, with first enabling patents for livestock using both CRISPR and TALENs gene-editing technologies.